William C Cushman

List of Publications by Citations

53 papers	13,690 citations	28 h-index	55 g-index
55 ext. papers	16,956 ext. citations	11.7 avg, IF	5.74 L-index

#	Paper	IF	Citations
53	2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA - Journal of the American Medical Association*, **2014**, 311, 507-20	27.4	5231
52	A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *New England Journal of Medicine*, **2015**, 373, 2103-16	59.2	3396
51	Effects of intensive blood-pressure control in type 2 diabetes mellitus. *New England Journal of Medicine*, **2010**, 362, 1575-85	59.2	2411
50	Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2019**, 321, 553-561	27.4	449
49	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). *Clinical Trials*, **2014**, 11, 532-46	2.2	300
48	Effects of Intensive BP Control in CKD. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 2812-2823	12.7	234
47	Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension*, **2014**, 64, 1012-21	8.5	152
46	Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. *JAMA - Journal of the American Medical Association*, **2019**, 322, 524-534	27.4	146
45	Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). *Hypertension*, **2018**, 71, 848-857	8.5	135
44	KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney International*, **2021**, 99, S1-S87	9.9	126
43	Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. *Hypertension*, **2017**, 69, 42-50	8.5	111
42	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. *Circulation*, **2018**, 137, 134-143	16.7	89
41	Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). *Circulation*, **2017**, 136, 440-450	16.7	71
40	Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. *Hypertension*, **2016**, 68, 888-95	8.5	71
39	Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. *Circulation: Heart Failure*, **2017**, 10,	7.6	67
38	The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. *Hypertension*, **2016**, 68, 39-45	8.5	60
37	SPRINT Trial Results: Latest News in Hypertension Management. *Hypertension*, **2016**, 67, 263-5	8.5	57

36	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. *Diabetes Care*, **2017**,	14.6	53
35	Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney International*, **2021**, 99, 559-569	9.9	51
34	Research Needs to Improve Hypertension Treatment and Control in African Americans. *Hypertension*, **2016**, 68, 1066-1072	8.5	49
33	Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. *New England Journal of Medicine*, **2021**, 384, 1921-1930	59.2	49
32	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). *Hypertension*, **2017**, 70, 751-758	8.5	48
31	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. *Journal of the American Heart Association*, **2018**, 7, e009326	6	45
30	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. *Journal of the American Society of Hypertension*, **2016**, 10, 847-856		39
29	Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans. *Hypertension*, **2014**, 64, 951-7	8.5	39
28	Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *Circulation*, **2011**, 124, 1811-8	16.7	39
27	Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events: Results From SPRINT. *Hypertension*, **2020**, 75, 660-667	8.5	29
26	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. *American Journal of Nephrology*, **2016**, 43, 271-80	4.6	28
25	Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. *Hypertension*, **2021**, 77, 692-705	8.5	28
24	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis. *Annals of Internal Medicine*, **2021**, 174, 58-68	8	15
23	Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. *Hypertension*, **2016**, 67, 550-5	8.5	13
22	Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline. *Annals of Internal Medicine*, **2021**, 174, 1270-1281	8	11
21	Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction: Potential Role of Diuretics. *JACC: Heart Failure*, **2019**, 7, 1032-1041	7.9	7
20	Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: The Diagnosis and Management of Hypertension in the Primary Care Setting. *Annals of Internal Medicine*, **2020**, 173, 904-913	8	4
19	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. *American Journal of Cardiology*, **2018**, 122, 1496-1505	3	3

18	Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial.. *JAMA Network Open*, **2022**, 5, e2143001	10.4	3
17	The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure: A Post Hoc Analysis of SPRINT. *Hypertension*, **2021**, 77, 813-822	8.5	3
16	A Method to Quantify Mean Hypertension Treatment Daily Dose Intensity Using Health Care System Data. *JAMA Network Open*, **2021**, 4, e2034059	10.4	3
15	Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. *Journal of the National Medical Association*, **2017**, 109, 172-181	2.3	2
14	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. *Journal of Hypertension*, **2018**, 36, 947-956	1.9	2
13	Real-world evidence supports optimally dosed thiazide-type diuretics as preferred in treatment regimens of older adults with hypertension. *Journal of the American Geriatrics Society*, **2015**, 63, 1045-7	5.6	2
12	Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. *Circulation: Heart Failure*, **2021**, CIRCHEARTFAILURE121008322	7.6	2
11	Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults : A Retrospective Observational Study. *Annals of Internal Medicine*, **2021**,	8	2
10	Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Intervention Trial). *American Journal of Kidney Diseases*, **2021**, 78, 48-56	7.4	2
9	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, 1345-1351	5.6	2
8	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 484-490	18.1	2
7	Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia. *Research in Social and Administrative Pharmacy*, **2021**, 17, 1469-1477	2.9	2
6	Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VATs Diuretic Comparison Project.. *Contemporary Clinical Trials*, **2022**, 106754	2.3	2
5	SPRINT Revisited: Updated Results and Implications. *Hypertension*, **2021**, 78, 1701-1710	8.5	2
4	Antihypertensive Medication Adherence, Stroke and Death. *Journal of General Internal Medicine*, **2010**, 25, 764-764	4	1
3	Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. *Journal of the American College of Cardiology*, **2021**, 77, 1977-1990	15.1	1
2	Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort Data. *Journal of the American Heart Association*, **2021**, 10, e020361	6	1
1	Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults.. *Annals of Internal Medicine*, **2022**, 175, W15-W16	8	